Chronic liver inflammation: Clinical implications beyond alcoholic liver disease

World Journal of Gastroenterology

Volumn 20, Issue 9, 2014, Pages 2168-2175

  Park, Byoung Jin ^a   Lee, Yong Jae ^b   Lee, Hye Ree ^b  

^a CHA University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Alcoholic liver disease; Bone disease; Cardiovascular disease; Immunologic disease; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; C REACTIVE PROTEIN; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; LIPOPOLYSACCHARIDE; PENTOXIFYLLINE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; PROBIOTIC AGENT;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ARTICLE; BONE DENSITY; BONE DISEASE; CARDIOVASCULAR DISEASE; CHRONIC HEPATITIS; DISEASE COURSE; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; IMMUNOPATHOLOGY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; QUALITY OF LIFE; ADVERSE EFFECTS; ANIMAL; BONE DISEASES; CARDIOVASCULAR DISEASES; COMPLICATION; DRINKING BEHAVIOR; IMMUNE SYSTEM DISEASES; LIVER DISEASES, ALCOHOLIC; METABOLISM; MICROBIOLOGY; PROGNOSIS; RISK FACTOR;

ALCOHOL DRINKING; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BONE DISEASES; CARDIOVASCULAR DISEASES; HUMANS; IMMUNE SYSTEM DISEASES; LIVER DISEASES, ALCOHOLIC; PROBIOTICS; PROGNOSIS; RISK FACTORS;

EID: 84895868033     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i9.2168     Document Type: Article

References (84)

1. Lieber CS, Jones DP, Decarli LM. Effects of prolonged ethanol intake: production of fatty liver despite adequate diets. J Clin Invest 1965; 44: 1009-1021 [PMID: 14322019 DOI: 10.1172/ JCI105200]
2. Song IH, Kim KS. Current status of liver diseases in Korea: hepatocellular carcinoma. Korean J Hepatol 2009; 15 Suppl 6: S50-S59 [PMID: 20037280 DOI: 10.3350/kjhep.2009.15.S6.S50]
3. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141: 1572-1585 [PMID: 21920463 DOI: 10.1053/j.gastro.2011.09.002]
4. Enomoto N, Ikejima K, Bradford BU, Rivera CA, Kono H, Goto M, Yamashina S, Schemmer P, Kitamura T, Oide H, Takei Y, Hirose M, Shimizu H, Miyazaki A, Brenner DA, Sato N, Thurman RG. Role of Kupffer cells and gut-derived endotoxins in alcoholic liver injury. J Gastroenterol Hepatol 2000; 15 Suppl: D20-D25 [PMID: 10759216 DOI: 10.1046/ j.1440-1746.2000.02179.x]
5. Wang HJ, Zakhari S, Jung MK. Alcohol, inflammation, and gut-liver-brain interactions in tissue damage and disease development. World J Gastroenterol 2010; 16: 1304-1313 [PMID: 20238396 DOI: 10.3748/wjg.v16.i11.1304]
6. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011; 6: 425-456 [PMID: 21073339 DOI: 10.1146/annurev-pathol-011110-130246]
7. Wang HJ, Gao B, Zakhari S, Nagy LE. Inflammation in alcoholic liver disease. Annu Rev Nutr 2012; 32: 343-368 [PMID: 22524187 DOI: 10.1146/annurev-nutr-072610-145138]
8. Park SH, Kim BI, Yun JW, Kim JW, Park DI, Cho YK, Sung IK, Park CY, Sohn CI, Jeon WK, Kim H, Rhee EJ, Lee WY, Kim SW. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol 2004; 19: 694-698 [PMID: 15151626 DOI: 10.1111/j.1440-1746.2004.03362.x]
9. Wang CC, Lin SK, Tseng YF, Hsu CS, Tseng TC, Lin HH, Wang LY, Kao JH. Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2009; 24: 1411-1416 [PMID: 19702910 DOI: 10.1111/ j.1440-1746.2009.05872.x]
10. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428-435 [PMID: 18650913 DOI: 10.1038/nature07201]
11. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15: 74-80 [PMID: 7512342]
12. Kogiso T, Moriyoshi Y, Shimizu S, Nagahara H, Shiratori K. High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population. J Gastroenterol 2009; 44: 313-321 [PMID: 19271113 DOI: 10.1007/s00535-009-0002-5]
13. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008; 103: 1372-1379 [PMID: 18510618 DOI: 10.1111/ j.1572-0241.2007.01774.x]
14. Bahcecioglu IH, Yalniz M, Ataseven H, Ilhan N, Ozercan IH, Seckin D, Sahin K. Levels of serum hyaluronic acid, TNFalpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology 2005; 52: 1549-1553 [PMID: 16201116]
15. Bhagat K, Vallance P. Effects of cytokines on nitric oxide pathways in human vasculature. Curr Opin Nephrol Hypertens 1999; 8: 89-96 [PMID: 9914865]
16. Kahaleh MB, Fan PS. Effect of cytokines on the production of endothelin by endothelial cells. Clin Exp Rheumatol 1997; 15: 163-167 [PMID: 9196868]
17. Bataller R, Sancho-Bru P, Ginès P, Lora JM, Al-Garawi A, Solé M, Colmenero J, Nicolás JM, Jiménez W, Weich N, Gutiérrez-Ramos JC, Arroyo V, Rodés J. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003; 125: 117-125 [PMID: 12851877 DOI: 10.1016/S0016-5085(03)00695-4]
18. Sookoian S, Castaño GO, Burgueño AL, Rosselli MS, Gianotti TF, Mallardi P, Martino JS, Pirola CJ. Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. Atherosclerosis 2010; 209: 585-591 [PMID: 19896127 DOI: 10.1016/j.atherosclerosis. 2009.10.011]
19. Sakuta H, Suzuki T. Alcohol consumption and plasma homocysteine. Alcohol 2005; 37: 73-77 [PMID: 16584970 DOI: 10.1016/j.alcohol.2005.12.005]
20. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-1050 [PMID: 9535670 DOI: 10.1056/NEJM199804093381507]
21. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354: 407-413 [PMID: 10437885 DOI: 10.1016/S0140-6736(98)11058-9]
22. Cook RT. Alcohol abuse, alcoholism, and damage to the immune system--a review. Alcohol Clin Exp Res 1998; 22: 1927-1942 [PMID: 9884135 DOI: 10.1111/j.1530-0277.1998. tb05900.x]
23. Chen CW, Jong GM, Shiau JJ, Hsiue TR, Chang HY, Chuang YC, Chen CR. Adult bacteremic pneumonia: bacteriology and prognostic factors. J Formos Med Assoc 1992; 91: 754-759 [PMID: 1362112]
24. Cortese MM, Wolff M, Almeido-Hill J, Reid R, Ketcham J, Santosham M. High incidence rates of invasive pneumococcal disease in the White Mountain Apache population. Arch Intern Med 1992; 152: 2277-2282 [PMID: 1444688 DOI: 10.1001/archinte.1992.00400230087015]
25. Kuikka A, Syrjänen J, Renkonen OV, Valtonen VV. Pneumococcal bacteraemia during a recent decade. J Infect 1992; 24: 157-168 [PMID: 1569306 DOI: 10.1016/0163-4453(92)92850-I]
26. Friedman LN, Sullivan GM, Bevilaqua RP, Loscos R. Tuberculosis screening in alcoholics and drug addicts. Am Rev Respir Dis 1987; 136: 1188-1192 [PMID: 3674581]
27. MacGregor RR, Louria DB. Alcohol and infection. Curr Clin Top Infect Dis 1997; 17: 291-315 [PMID: 9189671]
28. Bagasra O, Bachman SE, Jew L, Tawadros R, Cater J, Boden G, Ryan I, Pomerantz RJ. Increased human immunodeficiency virus type 1 replication in human peripheral blood mononuclear cells induced by ethanol: potential immunopathogenic mechanisms. J Infect Dis 1996; 173: 550-558 [PMID: 8627016 DOI: 10.1093/infdis/173.3.550]
29. Paronetto F. Immunologic reactions in alcoholic liver disease. Semin Liver Dis 1993; 13: 183-195 [PMID: 8393215 DOI: 10.1055/s-2007-1007348]
30. Gonzalez-Quintela A, Vidal C, Gude F. Alcohol, IgE and allergy. Addict Biol 2004; 9: 195-204 [PMID: 15511713 DOI: 10.1111/j.1369-1600.2004.tb00533.x]
31. González-Quintela A, Vidal C, Gude F. Alcohol-induced alterations in serum immunoglobulin e (IgE) levels in human subjects. Front Biosci 2002; 7: e234-e244 [PMID: 11991851]
32. Gonzalez-Quintela A, Dominguez-Santalla MJ, Perez LF, Lojo S, Vidal C. Serum levels of soluble CD30 and total IgE in alcoholics. Allergol Intern 2002; 51: 33-37
33. Sokhi RP, Anantharaju A, Kondaveeti R, Creech SD, Islam KK, Van Thiel DH. Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transpl 2004; 10: 648-653 [PMID: 15108256 DOI: 10.1002/lt.20104]
34. Ninkovic M, Love SA, Tom B, Alexander GJ, Compston JE. High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int 2001; 69: 321-326 [PMID: 11800228 DOI: 10.1007/s00223-001-2028-4]
35. Hay JE, Guichelaar MM. Evaluation and management of osteoporosis in liver disease. Clin Liver Dis 2005; 9: 747-766, viii [PMID: 16207574 DOI: 10.1016/j.cld.2005.07.003]
36. Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003; 125: 941-966 [PMID: 12949738 DOI: 10.1016/S0016-5085(03)01062-X]
37. Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002; 50 Suppl 1: i1-i9 [PMID: 11788576 DOI: 10.1136/gut.50.suppl_1.i1]
38. Sanchez AJ, Aranda-Michel J. Liver disease and osteoporosis. Nutr Clin Pract 2006; 21: 273-278 [PMID: 16772544 DOI: 10.1177/0115426506021003273]
39. Collier J. Bone disorders in chronic liver disease. Hepatology 2007; 46: 1271-1278 [PMID: 17886334 DOI: 10.1002/ hep.21852]
40. Cederbaum AI, Lu Y, Wu D. Role of oxidative stress in alcohol-induced liver injury. Arch Toxicol 2009; 83: 519-548 [PMID: 19448996 DOI: 10.1007/s00204-009-0432-0]
41. Setshedi M, Wands JR, Monte SM. Acetaldehyde adducts in alcoholic liver disease. Oxid Med Cell Longev 2010; 3: 178-185 [PMID: 20716942 DOI: 10.4161/oxim.3.3.12288]
42. Farfán Labonne BE, Gutiérrez M, Gómez-Quiroz LE, Konigsberg Fainstein M, Bucio L, Souza V, Flores O, Ortíz V, Hernández E, Kershenobich D, Gutiérrez-Ruíz MC. Acetaldehyde-induced mitochondrial dysfunction sensitizes hepatocytes to oxidative damage. Cell Biol Toxicol 2009; 25: 599-609 [PMID: 19137438 DOI: 10.1007/s10565-008-9115-5]
43. Kehrer JP. Free radicals as mediators of tissue injury and disease. Crit Rev Toxicol 1993; 23: 21-48 [PMID: 8471159 DOI: 10.3109/10408449309104073]
44. Knight JA. Free radicals: their history and current status in aging and disease. Ann Clin Lab Sci 1998; 28: 331-346 [PMID: 9846200]
45. Cederbaum AI. Iron and CYP2E1-dependent oxidative stress and toxicity. Alcohol 2003; 30: 115-120 [PMID: 12957295 DOI: 10.1016/S0741-8329(03)00104-6]
46. Singh M, Gupta S, Singhal U, Pandey R, Aggarwal SK. Evaluation of the oxidative stress in chronic alcoholics. J Clin Diagn Res 2013; 7: 1568-1571 [PMID: 24086841 DOI: 10.7860/ JCDR/2013/5596.3210]
47. Zakhari S. Overview: how is alcohol metabolized by the body? Alcohol Res Health 2006; 29: 245-254 [PMID: 17718403]
48. Lu Y, Zhuge J, Wang X, Bai J, Cederbaum AI. Cytochrome P450 2E1 contributes to ethanol-induced fatty liver in mice. Hepatology 2008; 47: 1483-1494 [PMID: 18393316 DOI: 10.1002/hep.22222]
49. Zhou Z, Wang L, Song Z, Lambert JC, McClain CJ, Kang YJ. A critical involvement of oxidative stress in acute alcohol-induced hepatic TNF-alpha production. Am J Pathol 2003; 163: 1137-1146 [PMID: 12937155 DOI: 10.1016/S0002-9440(10)63473-6]
50. McVicker BL, Tuma PL, Kharbanda KK, Lee SM, Tuma DJ. Relationship between oxidative stress and hepatic glutathione levels in ethanol-mediated apoptosis of polarized hepatic cells. World J Gastroenterol 2009; 15: 2609-2616 [PMID: 19496190 DOI: 10.3748/wjg.15.2609]
51. Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster MI, Thurman RG. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999; 117: 942-952 [PMID: 10500078 DOI: 10.1016/ S0016-5085(99)70354]
52. Hritz I, Mandrekar P, Velayudham A, Catalano D, Dolganiuc A, Kodys K, Kurt-Jones E, Szabo G. The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology 2008; 48: 1224-1231 [PMID: 18792393 DOI: 10.1002/hep.22470]
53. Wang H, Lafdil F, Kong X, Gao B. Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int J Biol Sci 2011; 7: 536-550 [PMID: 21552420 DOI: 10.7150/ijbs.7.536]
54. Mottaran E, Stewart SF, Rolla R, Vay D, Cipriani V, Moretti M, Vidali M, Sartori M, Rigamonti C, Day CP, Albano E. Lipid peroxidation contributes to immune reactions associated with alcoholic liver disease. Free Radic Biol Med 2002; 32: 38-45 [PMID: 11755315 DOI: 10.1016/S0891-5849(01)00757]
55. Thiele GM, Freeman TL, Klassen LW. Immunologic mechanisms of alcoholic liver injury. Semin Liver Dis 2004; 24: 273-287 [PMID: 15349805 DOI: 10.1055/s-2004-832940]
56. Olofsson P, Nylander G, Olsson P. Endotoxin: routes of transport in experimental peritonitis. Am J Surg 1986; 151: 443-446 [PMID: 3963300 DOI: 10.1016/0002-9610(86)90098-X]
57. Olofsson P, Nylander G, Olsson P. Endotoxin-transport routes and kinetics in intestinal ischemia. Acta Chir Scand 1985; 151: 635-639 [PMID: 4090892]
58. Ferrier L, Bérard F, Debrauwer L, Chabo C, Langella P, Buéno L, Fioramonti J. Impairment of the intestinal barrier by ethanol involves enteric microflora and mast cell activation in rodents. Am J Pathol 2006; 168: 1148-1154 [PMID: 16565490 DOI: 10.2353/ajpath.2006.050617]
59. Rao R. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. Hepatology 2009; 50: 638-644 [PMID: 19575462 DOI: 10.1002/hep.23009]
60. Fukui H, Brauner B, Bode JC, Bode C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol 1991; 12: 162-169 [PMID: 2050995 DOI: 10.101 6/0168-8278(91)90933-3]
61. Bode JC, Bode C, Heidelbach R, Dürr HK, Martini GA. Jejunal microflora in patients with chronic alcohol abuse. Hepatogastroenterology 1984; 31: 30-34 [PMID: 6698486]
62. Hauge T, Persson J, Danielsson D. Mucosal bacterial growth in the upper gastrointestinal tract in alcoholics (heavy drinkers). Digestion 1997; 58: 591-595 [PMID: 9438608 DOI: 10.1159/000201507]
63. Lambert JC, Zhou Z, Wang L, Song Z, McClain CJ, Kang YJ. Preservation of intestinal structural integrity by zinc is independent of metallothionein in alcohol-intoxicated mice. Am J Pathol 2004; 164: 1959-1966 [PMID: 15161632 DOI: 10.1016/ S0002-9440(10)63756-X]
64. Thurman RG. II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am J Physiol 1998; 275: G605-G611 [PMID: 9756487]
65. Day CP. Treatment of alcoholic liver disease. Liver Transpl 2007; 13: S69-S75 [PMID: 17969070 DOI: 10.1002/lt.21336]
66. Tan HH, Virmani S, Martin P. Controversies in the management of alcoholic liver disease. Mt Sinai J Med 2009; 76: 484-498 [PMID: 19787655 DOI: 10.1002/msj.20135]
67. Spahr L, Rubbia-Brandt L, Frossard JL, Giostra E, Rougemont AL, Pugin J, Fischer M, Egger H, Hadengue A. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002; 37: 448-455 [PMID: 12217597]
68. Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, Davion T, Oberti F, Broët P, Emilie D. A doubleblind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390-1397 [PMID: 15122768 DOI: 10.1002/hep.20206]
69. Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, Boardman L, Gores GJ, Harmsen WS, McClain CJ, Kamath PS, Shah VH. A randomized, double-blinded, placebocontrolled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135: 1953-1960 [PMID: 18848937 DOI: 10.1053/j.gastro.2008.08.057]
70. Vendemiale G, Altomare E, Trizio T, Le Grazie C, Di Padova C, Salerno MT, Carrieri V, Albano O. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol 1989; 24: 407-415 [PMID: 2781235]
71. Purohit V, Abdelmalek MF, Barve S, Benevenga NJ, Halsted CH, Kaplowitz N, Kharbanda KK, Liu QY, Lu SC, McClain CJ, Swanson C, Zakhari S. Role of S-adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: summary of a symposium. Am J Clin Nutr 2007; 86: 14-24 [PMID: 17616758]
72. Mato JM, Cámara J, Fernández de Paz J, Caballería L, Coll S, Caballero A, García-Buey L, Beltrán J, Benita V, Caballería J, Solà R, Moreno-Otero R, Barrao F, Martín-Duce A, Correa JA, Parés A, Barrao E, García-Magaz I, Puerta JL, Moreno J, Boissard G, Ortiz P, Rodés J. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999; 30: 1081-1089 [PMID: 10406187]
73. Medici V, Virata MC, Peerson JM, Stabler SP, French SW, Gregory JF, Albanese A, Bowlus CL, Devaraj S, Panacek EA, Richards JR, Halsted CH. S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial. Alcohol Clin Exp Res 2011; 35: 1960-1965 [PMID: 22044287 DOI: 10.1111/j.1530-0277.2011.01547.x]
74. Bishayee A, Darvesh AS, Politis T, McGory R. Resveratrol and liver disease: from bench to bedside and community. Liver Int 2010; 30: 1103-1114 [PMID: 20557453 DOI: 10.1111/ j.1478-3231.2010.02295.x]
75. Sindhu ER, Firdous AP, Preethi KC, Kuttan R. Carotenoid lutein protects rats from paracetamol-, carbon tetrachloride-and ethanol-induced hepatic damage. J Pharm Pharmacol 2010; 62: 1054-1060 [PMID: 20663040 DOI: 10.1111/ j.2042-7158.2010.01123.x]
76. Stewart S, Prince M, Bassendine M, Hudson M, James O, Jones D, Record C, Day CP. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 2007; 47: 277-283 [PMID: 17532088 DOI: 10.1016/j.jhep.2007.03.027]
77. Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O'Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis--a randomised clinical trial. J Hepatol 2006; 44: 784-790 [PMID: 16469404 DOI: 10.1016/j.jhep.2005.11.039]
78. Nanji AA, Khettry U, Sadrzadeh SM. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc Soc Exp Biol Med 1994; 205: 243-247 [PMID: 8171045]
79. Kirpich IA, Solovieva NV, Leikhter SN, Shidakova NA, Lebedeva OV, Sidorov PI, Bazhukova TA, Soloviev AG, Barve SS, McClain CJ, Cave M. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 2008; 42: 675-682 [PMID: 19038698 DOI: 10.1016/j.alcohol.2008.08.006]
80. Ewaschuk JB, Diaz H, Meddings L, Diederichs B, Dmytrash A, Backer J, Looijer-van Langen M, Madsen KL. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am J Physiol Gastrointest Liver Physiol 2008; 295: G1025-G1034 [PMID: 18787064 DOI: 10.1152/ajpgi.90227.2008]
81. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-1081 [PMID: 20335583 DOI: 10.1056/NEJMoa0907893]
82. Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut 2009; 58: 704-720 [PMID: 19359436 DOI: 10.1136/gut.2008.156307]
83. Ki SH, Park O, Zheng M, Morales-Ibanez O, Kolls JK, Bataller R, Gao B. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription Hepatology 2010; 52: 1291-1300 [PMID: 20842630 DOI: 10.1002/hep.23837]
84. Lemmers A, Moreno C, Gustot T, Maréchal R, Degré D, Demetter P, de Nadai P, Geerts A, Quertinmont E, Vercruysse V, Le Moine O, Devière J. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 2009; 49: 646-657 [PMID: 19177575 DOI: 10.1002/hep.22680]